Fulgent Genetics reported strong third-quarter results for 2025, showcasing robust growth in laboratory services and significant progress in its therapeutic development pipeline.

• Laboratory services revenue reached nearly $84 million, with a year-over-year growth of 16.4% driven by the Precision Diagnostics and Biopharma segments.
• Fulgent is raising its outlook for 2025, reflecting sustained business momentum and successful integration of AI technologies in its operations.
• Phase II trials for lead candidate FID-007 demonstrated meaningful efficacy in treating recurrent or metastatic head and neck cancer, with overall response rates of 51%.
• FID-022 has entered Phase I trials, targeting multiple solid tumors, indicating an expanding and diversified pipeline.
• The company continues to enhance diagnostic services, recently launching a rapid whole genome sequencing offering that provides preliminary results within 48 hours.